LONDON – Healx Ltd. has raised a $56 million series B after demonstrating its artificial intelligence-driven drug repurposing platform can systematically uncover treatments for rare diseases.

SUZHOU, China – The rare disease space continues to be an area of focus for across the sector worldwide, and China is no exception, with regulators rolling out long-awaited incentives and drugmakers viewing the field as a promising area to drive growth.